Comparative Pharmacology
Head-to-head clinical analysis: CEFIZOX IN PLASTIC CONTAINER versus CEFOXITIN IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFIZOX IN PLASTIC CONTAINER versus CEFOXITIN IN PLASTIC CONTAINER.
CEFIZOX IN PLASTIC CONTAINER vs CEFOXITIN IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to penicillin-binding proteins (PBPs) in bacterial cell wall, inhibiting peptidoglycan cross-linking, leading to cell lysis and death.
Cefoxitin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP1a, PBP1b, and PBP2, thereby inhibiting transpeptidation and leading to cell lysis. It is a cephamycin antibiotic resistant to beta-lactamase hydrolysis due to a 7-alpha-methoxy group.
1-2 g IV/IM every 8-12 hours; severe infections: up to 2 g every 6-8 hours; maximum 12 g/day.
1-2 g IV every 6-8 hours; maximum 12 g/day
None Documented
None Documented
1.5-2 hours; prolonged to 10-30 hours in severe renal impairment (CrCl <10 mL/min)
Terminal elimination half-life: 0.7-1.5 hours (approximately 45-90 minutes); prolonged to 2-6 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 10-20 hours in severe renal impairment (CrCl <10 mL/min).
Primarily renal (80-90% unchanged), with biliary/fecal elimination being minor (<10%)
Renal: 85-95% unchanged via glomerular filtration and tubular secretion; biliary: <2%; fecal: trace.
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic